neuromyelitis is a rare autoimmune inflammatory disorder characterized by selective, severe involvement of the optic nerves (optic neuritis) and spinal cord (transverse myelitis), classically presenting as neuromyelitis optica (NMO) or, in its broadened diagnostic form, neuromyelitis optica spectrum disorder (NMOSD). It is distinguished from multiple sclerosis by its predilection for the optic nerves and longitudinally extensive transverse myelitis (LETM) lesions spanning three or more contiguous vertebral segments, its association with serum aquaporin-4 IgG** (AQP4-IgG) or myelin oligodendrocyte glycoprotein IgG (MOG-IgG) autoantibodies**, and its typically more severe relapsing clinical course with incomplete recovery between attacks. The underlying pathophysiology in AQP4-seropositive disease involves autoantibody-mediated destruction of astrocytic aquaporin-4 water channels at the blood-brain barrier, triggering complement-dependent cytotoxicity, neuroinflammation, and secondary demyelination — a mechanism distinct from the primary oligodendrocyte-directed injury of multiple sclerosis. Clinically, attacks present as sudden severe visual loss, unilateral or bilateral optic neuritis, and ascending paralysis or sensory loss, often with neurogenic bladder dysfunction and intractable nausea or vomiting due to area postrema involvement. The principal inpatient coding designation is G36.0 (Neuromyelitis optica [Devic]), with secondary coding for optic neuritis by laterality (H46.01, H46.02, H46.03) and transverse myelitis via G37.3 or G04.89 when documented as separately treated manifestations. neuromyelitis is commonly confused with multiple sclerosis — the critical distinction is that NMO is AQP4-IgG seropositive in approximately 73-80% of cases, demonstrates longitudinally extensive spinal cord lesions, and lacks the periventricular, juxtacortical, and infratentorial white matter plaques that define MS on MRI.
Noun-forming suffix — “inflammation of” — denoting an acute or chronic inflammatory condition of the preceding structure
The compound term entered English in the 1890s as neuromyelitis (noun), constructed directly from Greek elements, with clinical formalization by French physician Eugène Devic in 1894 when he described the distinct syndrome of simultaneous optic neuritis and acute myelitis — subsequently eponymized as Devic’s disease. The adjective form neuromyelitic appeared in parallel clinical use by the early 1900s. The root myel- (“marrow / spinal cord”) connects neuromyelitis to the broader -myel- root family: encephalomyelitis (enkephalos + myelos + -itis → brain and spinal cord inflammation), myelopathy (myel- + -pathy → spinal cord disease, non-inflammatory), and myelitis (myel- + -itis → spinal cord inflammation without optic involvement). The prefix neuro- is among the most productive in medical terminology, also appearing in neuralgia, neuropathy, neuritis, and neurofibromatosis.
🔀 ALIASES / ALTERNATE TERMS
Neuromyelitic(adjective form — appears clinically as “neuromyelitic attacks,” “neuromyelitic lesions,” “neuromyelitic syndrome”)
NMO(standard abbreviation for neuromyelitis optica; used interchangeably with Devic’s disease in clinical documentation; indexed under G36.0)
Devic’s disease(eponymous synonym; originally described in 1894 as a monophasic syndrome of optic neuritis plus myelitis; now recognized as typically relapsing; coded G36.0)
NMOSD(expanded clinical form — Neuromyelitis Optica Spectrum Disorder; includes AQP4-IgG seropositive, MOG-IgG seropositive, and seronegative cases meeting 2015 International Panel criteria; still coded G36.0 in ICD-10-CM)
Optic neuritis(hallmark visual manifestation of NMO — demyelinating inflammation of the optic nerve; may be unilateral or bilateral; coded by laterality: H46.01, H46.02, H46.03; often the presenting attack)
Transverse myelitis(hallmark spinal manifestation — inflammation spanning the full cross-sectional width of the spinal cord; in NMO, classically longitudinally extensive spanning ≥3 vertebral segments; coded G37.3 or G04.89)
AQP4-IgG seropositive NMO(most common antibody-defined subtype — aquaporin-4 autoantibody positive; seropositive in ~73-80% of NMOSD cases; most severe phenotype with highest relapse frequency and disability accumulation)
MOGAD(MOG-IgG Associated Disease — distinct antibody-defined subtype with overlapping NMO phenotype but different pathophysiology, typically better recovery, and distinct treatment response; also coded G36.0 in current ICD-10-CM)
Area postrema syndrome(a NMO-specific brainstem manifestation — intractable nausea, vomiting, or hiccups from area postrema lesion at the dorsal medulla; a 2015 NMOSD diagnostic criterion; code the symptom separately when documented without explicit NMO diagnosis)
LETM(Longitudinally Extensive Transverse Myelitis — radiographic descriptor for spinal cord lesion spanning ≥3 contiguous vertebral segments on MRI; highly characteristic of NMO vs. MS; key documentation trigger to prompt provider query for NMOSD confirmation)
🔗 RELATED TERMS
Multiple sclerosis — primary clinical differential diagnosis; shares CNS demyelination but differs in lesion distribution (periventricular, juxtacortical, infratentorial in MS vs. optic nerve and long spinal cord in NMO), antibody profile (AQP4-IgG typically negative in MS), and cord lesion length (short segments in MS vs. LETM in NMO); coded G35.D
Encephalomyelitis — shares the myel- root; inflammation of both brain and spinal cord; broader CNS involvement than neuromyelitis; acute disseminated encephalomyelitis (ADEM) is a key differential in first-attack NMO; see G04.00
Myelitis — spinal cord inflammation alone without the optic nerve component; may represent a single-attack NMO forme fruste or isolated syndrome; coded G37.3 in demyelinating context or G04.89 otherwise
Optic neuritis — demyelinating inflammation of the optic nerve; the hallmark visual attack of NMO; may be the presenting, isolated, or recurrent manifestation; coded by laterality H46.01-H46.03
Aquaporin-4 (AQP4) — the astrocytic water channel protein serving as the primary autoantigen in seropositive NMOSD; AQP4-IgG seropositivity is pathognomonic for NMOSD and guides biologic treatment selection; its absence shifts the differential toward MS or MOGAD
AQP4-IgG — the defining autoantibody of seropositive NMOSD; binds aquaporin-4 on astrocyte end-feet at the blood-brain barrier, activating complement cascade and triggering astrocytopathy; distinguishes NMO from MS at the serologic level
Complement-dependent cytotoxicity — primary effector mechanism in AQP4-IgG+ NMO; AQP4-IgG binding activates the complement cascade leading to membrane attack complex formation, astrocyte destruction, and secondary neuroinflammation with demyelination
ADEM(Acute Disseminated Encephalomyelitis) — monophasic inflammatory demyelinating condition that can mimic NMO on first presentation; distinguished by younger age, encephalopathy, and multifocal MRI pattern without LETM; coded G04.00, G04.01
MOGAD — a distinct but phenotypically overlapping autoimmune CNS demyelinating disease defined by MOG-IgG seropositivity; presents with optic neuritis and/or myelitis but with characteristically better recovery and different treatment response than AQP4-IgG+ NMO; both fall under G36.0 in ICD-10-CM
Neuritis — inflammation of a nerve; shares the neuro- root; optic neuritis (H46.0x) is the cranial nerve II form that defines the visual attack component of NMO
Visual evoked potential (VEP) — primary electrophysiologic tool for evaluating optic nerve conduction delay due to demyelination; CPT 95930; abnormal prolongation of P100 latency supports optic neuritis diagnosis in NMO evaluation
Acute transverse myelitis in demyelinating disease of central nervous system — assign for LETM documented in the setting of confirmed or suspected CNS demyelinating disease
Acute disseminated encephalomyelitis and encephalomyelitis, unspecified — assign when ADEM presentation is in the NMO differential or prior to antibody confirmation
Postinfectious acute disseminated encephalitis and encephalomyelitis — use when myelitis or encephalomyelitis is temporally related to a preceding infection
MRI cervical spine, without and with contrast — primary imaging for LETM lesion characterization; NMO-characteristic lesion spans ≥3 vertebral segments with central cord signal change
MRI brain, without and with contrast — performed to assess area postrema, brainstem, and white matter lesion pattern; distinguishes NMO from MS by lesion distribution
Intravenous infusion, therapy/prophylaxis/diagnosis, initial, up to 1 hour — primary billing code for high-dose IV methylprednisolone (Solu-Medrol), the standard acute NMO attack treatment
Spinal puncture, lumbar, diagnostic — CSF analysis supports NMO vs. MS differentiation; NMO typically shows mild pleocytosis and absent oligoclonal bands in approximately 80% of cases
EMG, needle, each extremity, with related paraspinal areas — used to exclude lower motor neuron disease when NMO myelitis produces flaccid weakness mimicking peripheral neuropathy
⚠️ Coding Note: In inpatient profee settings, G36.0 (Neuromyelitis optica [Devic]) is the correct principal code for all NMO and NMOSD encounters regardless of antibody status — do not assign a separate myelitis or optic neuritis code as principal when the full NMO syndrome is confirmed, though H46.01, H46.02, or H46.03 may be reported as additional diagnoses when optic neuritis is a separately evaluated or treated manifestation. Sequencing alert: when the NMO attack is the stated reason for admission, G36.0 leads; if admission is driven by an acute complication such as respiratory failure from high cervical myelitis, sequence the complication first and G36.0 as additional. Undercoding risk: providers frequently document only “transverse myelitis” or “optic neuritis” in their notes without explicitly writing NMO — when AQP4-IgG seropositivity is confirmed and both hallmarks are present in the record, query the provider to confirm the NMOSD diagnosis, as the code shift from G37.3 or H46.00 to G36.0 carries significant DRG weight impact. WPS (Jurisdiction 5) follows CMS policy for therapeutic apheresis (36514) in NMOSD — documentation of refractoriness to IV corticosteroids must appear in the record before billing PLEX; absence of this documentation is a common denial trigger. For biologic treatment authorization (eculizumab, inebilizumab, satralizumab), most WI payer contracts — including UHC and BCBS of WI — require explicit AQP4-IgG seropositive documentation in the record, not merely an NMOSD diagnosis, so serology results must be present and linked in the note.